Nature of the Event
This is a regulatory disclosure made pursuant to Regulation 30 read with Items 1 and 5 of Para A, Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It concerns the acquisition of control over a joint venture entity, PT Kerala Ayurveda Bali (PT KAB), making it a subsidiary of Kerala Ayurveda Limited (KAL).
Key Transaction Details
KAL's wholly owned subsidiary, Nutraveda Pte. Ltd., Singapore (Nutraveda), along with Ms. Monica Mohindra and PT KAB, executed a Novation and Addendum dated October 29, 2026. This agreement novated the rights and obligations of KAL under a prior Memorandum of Understanding (MoU dated September 20, 2022) to Nutraveda. Concurrently, the rights and obligations of Mr. Arvind Mohindra under the original MoU were novated/assigned to Ms. Monica Mohindra.
Pursuant to this agreement, Nutraveda was granted the right to appoint 2 of the 3 directors on the board of PT KAB. This granted Nutraveda control over PT KAB, effective from October 29, 2026, thereby making PT KAB a subsidiary of KAL.
The transaction did not involve any change in the shareholding of PT KAB; Nutraveda and Ms. Monica Mohindra continue to hold 50% of its equity share capital each. No consideration was payable in connection with this acquisition of control.
Dates and Regulatory Compliance
The Novation and Addendum was executed on October 29, 2026. The company received the copies of the executed document on November 17, 2026, and filed this disclosure with the exchange on November 18, 2026. The company stated the delay in disclosure from the execution date was inadvertent and regretted.
The disclosure includes Annexure A and Annexure B as required by SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
Details from Annexure A (Acquisition of Control)
- Target Entity: PT Kerala Ayurveda Bali, Indonesia (PT KAB). It is a joint venture with a nil turnover.
- Related Party Transaction: The acquisition falls under related party transactions as Nutraveda is a wholly owned subsidiary of KAL. Mr. Ramesh Vangal, Chairman of KAL, is a nominee director on the board of PT KAB. The transaction is reported to be on an arm's length basis.
- Industry: The entity belongs to the Ayurveda wellness and resorts industry.
- Objects and Impact: The object was to acquire majority board control, making PT KAB a step-down subsidiary. There is no financial impact, change in shareholding, or payable consideration.
- Approvals: No governmental or regulatory approvals were required in India. Only applicable Indonesian corporate filings are needed.
- Completion: The acquisition was effective on October 29, 2026.
- Background on PT KAB: It was incorporated in Indonesia on October 30, 2025, and operates in the Ayurveda wellness and resort business. It has a nil turnover history.
Details from Annexure B (Amendment of Agreement)
- Parties: Nutraveda, Ms. Monica Mohindra, and PT KAB.
- Purpose: To novate KAL's rights and obligations under the joint venture MoU to Nutraveda and to record the new governance structure for PT KAB.
- Shareholding: KAL holds 100% of Nutraveda, which in turn holds 50% of PT KAB.
- Significant Terms: The key term is Nutraveda's right to appoint 2 of the 3 directors on PT KAB's board. KAL is fully released from its obligations under the original MoU.
- Related Party: Nutraveda is a related party as a wholly owned subsidiary of KAL. The transaction is reported to be on an arm's length basis.
- Amendment Details: The original agreement was an MoU between KAL and Mr. Arvind Mohindra dated September 20, 2022. The amended agreement is the Novation and Addendum between Nutraveda, Ms. Monica Mohindra, and PT KAB, executed on October 29, 2026. The impact is the novation of obligations and the change in control.